[go: up one dir, main page]

NO20053623L - Derivater av prostaglandiner for behandling av abdominalt ubehag - Google Patents

Derivater av prostaglandiner for behandling av abdominalt ubehag

Info

Publication number
NO20053623L
NO20053623L NO20053623A NO20053623A NO20053623L NO 20053623 L NO20053623 L NO 20053623L NO 20053623 A NO20053623 A NO 20053623A NO 20053623 A NO20053623 A NO 20053623A NO 20053623 L NO20053623 L NO 20053623L
Authority
NO
Norway
Prior art keywords
treatment
prostaglandins
derivatives
abdominal discomfort
chloride channel
Prior art date
Application number
NO20053623A
Other languages
English (en)
Other versions
NO20053623D0 (no
NO335441B1 (no
Inventor
Ryuji Ueno
Sachiko Kuno
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32717850&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20053623(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sucampo Ag filed Critical Sucampo Ag
Publication of NO20053623D0 publication Critical patent/NO20053623D0/no
Publication of NO20053623L publication Critical patent/NO20053623L/no
Publication of NO335441B1 publication Critical patent/NO335441B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/56—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing rings other than six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Det er beskrevet en ny anvendelse av en kloridkanalåpner, spesielt en prostaglandinforbindelse, for behandling av abdominalt ubehag. Videre er det beskrevet en ny anvendelse av en kloridkanalåpner, spesielt en prostaglandinforbindelse, for behandling av funksjonelle gastro-intestinale forstyrrelser.
NO20053623A 2002-12-27 2005-07-26 Anvendelse av en prostaglandinforbindelse til fremstilling av et farmasøytisk preparat for behandling av irritabel tarm-syndrom og/eller funksjonell dyspepsi NO335441B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43646202P 2002-12-27 2002-12-27
US43646302P 2002-12-27 2002-12-27
PCT/JP2003/016857 WO2004060377A1 (en) 2002-12-27 2003-12-26 Derivatives of prostaglandins for treating abdominal discomfort

Publications (3)

Publication Number Publication Date
NO20053623D0 NO20053623D0 (no) 2005-07-26
NO20053623L true NO20053623L (no) 2005-09-26
NO335441B1 NO335441B1 (no) 2014-12-15

Family

ID=32717850

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053623A NO335441B1 (no) 2002-12-27 2005-07-26 Anvendelse av en prostaglandinforbindelse til fremstilling av et farmasøytisk preparat for behandling av irritabel tarm-syndrom og/eller funksjonell dyspepsi

Country Status (15)

Country Link
US (3) US7795312B2 (no)
EP (2) EP1575596B1 (no)
JP (2) JP4889219B2 (no)
KR (2) KR101164838B1 (no)
CN (1) CN1753680B (no)
AR (1) AR042670A1 (no)
AU (1) AU2003292556B2 (no)
BR (1) BRPI0317740B8 (no)
CA (1) CA2510051C (no)
ES (1) ES2591252T3 (no)
MX (1) MXPA05006981A (no)
NO (1) NO335441B1 (no)
NZ (1) NZ541110A (no)
TW (1) TWI336254B (no)
WO (1) WO2004060377A1 (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR037524A1 (es) * 2001-11-14 2004-11-17 Sucampo Ag Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
US8114911B2 (en) * 2002-10-23 2012-02-14 Sucampo Ag Prostaglandin compounds for the treatment of obesity
WO2005002588A1 (en) * 2003-07-03 2005-01-13 Sucampo Ag Enteric coated composition comprising prostaglandin analogs as chloride channel opener
TWI387454B (zh) * 2004-09-02 2013-03-01 蘇坎波公司 治療胃腸道疾病之方法及組成物
CN101180096B (zh) * 2005-03-21 2015-04-22 苏坎波公司 用于治疗粘膜疾病的方法和组合物
US20060281818A1 (en) 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
CN101198334B (zh) * 2005-04-12 2013-02-06 苏坎波公司 前列腺素化合物和质子泵抑制剂用于治疗肠胃病的联合应用
US7868045B2 (en) 2006-09-06 2011-01-11 Sucampo Ag Method for promoting gastrointestinal bicarbonate secretion
WO2008108322A2 (en) * 2007-02-27 2008-09-12 Sucampo Ag Composition and method for protecting mitochondria
US20090030072A1 (en) 2007-07-03 2009-01-29 Sucampo Ag Pharmaceutical combination of opioid and prostaglandin compound
US20090012165A1 (en) * 2007-07-03 2009-01-08 Sucampo Ag Pharmaceutical combination of nsaid and prostaglandin compound
JP5797655B2 (ja) * 2009-09-18 2015-10-21 アドラー・コーポレーション 消化管障害のためのオピオイド受容体アンタゴニストの使用
IT1402047B1 (it) * 2010-10-19 2013-08-28 Cross Pharma Sa Uso del mexiprostil nel trattamento delle malattie infiammatorie intestinali
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
CA2870252A1 (en) * 2012-04-23 2013-10-31 Sucampo Ag Method for treating irritable bowel syndrome with diarrhea
SG10201705989YA (en) 2012-10-15 2017-08-30 Epizyme Inc Substituted benzene compounds
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1581886A (en) * 1977-05-26 1980-12-31 May & Baker Ltd Prostanol derivatives
CA1322749C (en) 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
US5221763A (en) 1987-04-30 1993-06-22 R-Tech Ueno, Ltd. Prostaglandins of the F series
JPH0681728B2 (ja) * 1987-10-02 1994-10-19 株式会社上野製薬応用研究所 下 剤
US5317032A (en) 1987-10-02 1994-05-31 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandin cathartic
JP2579193B2 (ja) 1988-07-19 1997-02-05 小野薬品工業株式会社 １６，１６−ジフルオロ−１５−オキソ−１５−デオキシｐｇｅ誘導体
CA2039420C (en) 1990-04-04 1996-12-10 Ryuji Ueno Treatment of cataract with 15-keto-prostaglandin compounds
EP0455448B1 (en) 1990-05-01 1998-12-09 R-Tech Ueno Ltd. Treatment of pancreatic disease with 15-keto-prostaglandin E compounds
CA2150287C (en) 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
DK0857718T3 (da) 1996-06-10 2002-12-16 Sucampo Ag Endothelinantagonist
US6046239A (en) * 1997-08-05 2000-04-04 American Home Products Corporation Anthranilic acid analogs
ATE401894T1 (de) * 1997-11-28 2008-08-15 Sucampo Ag Verwendung von 15-keto-prostaglandin-e verbindungen als endothelin antagonisten
US6492417B1 (en) * 1997-12-22 2002-12-10 Alcon Manufacturing, Ltd. 11-deoxy-16-fluoro-PGF2α analogs as FP receptor antagonists
PT1220849E (pt) 1999-10-15 2004-10-29 Sucampo Ag Composicao de compostos biciclicos e metodo para a sua estabilizacao
DE60139002D1 (de) * 2000-04-06 2009-07-30 Sucampo Ag Gallensäurefördernde zusammensetzung für lebertransplantation welche ein 15-keto prostaglandin enthält
US6414016B1 (en) 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
TWI302100B (en) * 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
ATE387204T1 (de) * 2001-05-18 2008-03-15 Sucampo Ag Zusammensetzung mit induzierendem kathartischen effekt
MXPA04002006A (es) * 2001-08-31 2004-06-07 Sucampo Ag Analogos de prostagladina como abridor del canal de cloruro.
AR037524A1 (es) * 2001-11-14 2004-11-17 Sucampo Ag Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
US7732487B2 (en) * 2001-11-19 2010-06-08 Sucampo Ag Method for treating a disease or condition responsive to opening of C1C-2 channel

Also Published As

Publication number Publication date
BRPI0317740B1 (pt) 2018-09-18
BRPI0317740B8 (pt) 2021-05-25
KR101164838B1 (ko) 2012-07-11
AU2003292556B2 (en) 2009-09-10
EP2281564A2 (en) 2011-02-09
AU2003292556A1 (en) 2004-07-29
CA2510051A1 (en) 2004-07-22
TW200418491A (en) 2004-10-01
KR20120045051A (ko) 2012-05-08
CA2510051C (en) 2016-07-05
JP2012031202A (ja) 2012-02-16
NO20053623D0 (no) 2005-07-26
KR20050086950A (ko) 2005-08-30
NZ541110A (en) 2008-11-28
EP2281564A3 (en) 2012-09-05
US20100298424A1 (en) 2010-11-25
EP1575596A1 (en) 2005-09-21
US7795312B2 (en) 2010-09-14
CN1753680B (zh) 2010-12-08
TWI336254B (en) 2011-01-21
WO2004060377A1 (en) 2004-07-22
NO335441B1 (no) 2014-12-15
US20040138308A1 (en) 2004-07-15
JP4889219B2 (ja) 2012-03-07
ES2591252T3 (es) 2016-11-25
MXPA05006981A (es) 2005-12-14
BR0317740A (pt) 2005-11-22
US20130217770A1 (en) 2013-08-22
JP2006513232A (ja) 2006-04-20
EP1575596B1 (en) 2016-06-22
AR042670A1 (es) 2005-06-29
CN1753680A (zh) 2006-03-29

Similar Documents

Publication Publication Date Title
NO20053623L (no) Derivater av prostaglandiner for behandling av abdominalt ubehag
ATE491703T1 (de) Phthalazinonderivate
HRP20090281T1 (hr) 1,2,3,4-tetrasubstituirani indol za liječenje respiratornih bolesti
ATE440603T1 (de) 8-hydroxychinolinderivate
JO2764B1 (en) Indole derivatives or benzimidazole derivatives to modify the enzyme AKP kinase
CY1113578T1 (el) 2,3-διυδρο-6-νιτροϊμιδαζο 2,1 -b-οξαζολια
UA83257C2 (en) Allosteric modulators of metabotropic glutamate receptors
EA200301142A1 (ru) Производные гетероциклилокси-, -тиокси- и -аминобензазола в качестве лигандов 5-гидрокситриптамина-6
ATE399770T1 (de) Tachykininrezeptorantagonisten
NO20053042L (no) Anvendelse av spongosin (2-metoksyadenosin) for behandling av smerte, saerlig hyperalgesi.
DE602005023197D1 (de) -muscarinrezeptors
NO20062663L (no) Nukleinsyre som spesifikt binder bioaktivt ghrelin
DK1501417T3 (da) Stomamåleanordning
PL371127A1 (en) 6-aminomorphinane derivatives, method for the production and use thereof
HRP20080057T3 (en) 9,10-alpha,alpha-oh-taxane analogs and methods for production thereof
UA90496C2 (ru) 18-метил-19-нор-17-прегн-4-эн-21,17-карболактоны, а также лекарственный препарат, который их содержит
UA88773C2 (ru) Способ лечения раздражения мочевого пузыря и чрезмерно активного мочевого пузыря
NO20014241D0 (no) C16-umettede FP-selektive prostaglandinanaloger
SG139747A1 (en) Inhibitors of the mutant form of kit
SE0101082D0 (sv) Novel use
EP1667976A4 (en) Isoquinolinone POTASSIUM CHANNEL INHIBITORS
DE60128100D1 (de) Analgetisches arzneimittel
SE0200198D0 (sv) New use
BRPI0412694A (pt) compostos
EA200600898A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees